Category Archives: Research and Development

Budget cuts threaten HIV vaccine development, say experts

By on .

New HIV infections would decrease by 40 percent within ten years after the launch of an HIV vaccine, experts said at an HIV Vaccine Awareness Day event on Monday hosted by AVAC, IAVI and the Bill and Melinda Gates Foundation. Advancements in technology have paved the way for an effective HIV vaccine, but progress is threatened […]

AIDS vaccine update: With Thai trial, broadly neutralizing antibodies, new technologies and monkeys that met the SIV challenge, “we’re closer than ever”

By on .

NIH AIDS Vaccine Research Program Director: “The future of HIV-1 Vaccines is bright.” In 1997, scientists announced the birth of Dolly the cloned sheep, a computer named Deep Blue beat reigning chess champion Gary Kasparov, and the Hubble telescope brought the far reaches of outer space closer. President Bill Clinton pointed to all of these […]

International Partnership for Microbicides, pharmaceutical company agreement sets path for woman-controlled HIV prevention

By on .

The announcement today that Janssen R&D Ireland pharmaceutical company will give the nonprofit International Partnership for Microbicides exclusive worldwide rights to develop, make and market sexual and reproductive health products with the antiretroviral dapivirine was heralded by both organizations as a stride for global public health in general, and HIV prevention for women in particular. The […]

AVAC: HIV vaccine, microbicides, PrEP trial results say reality must guide research

By on .

For all the graphics illustrating results of HIV prevention trials in recent years, the Venn diagram on the cover of Research & Reality, the report released by AVAC today, may be the one that depicts the sum of their findings. Which is really saying something, when one considers the up-and-down nature of prevention research results […]

Report shows U.S. HIV research investment, progress; projects lasting impact from cuts

By on .

With the United States funding 70 percent of the world’s research and development of biomedical answers to HIV prevention, progress that has yielded the potential for immediate advances against the global epidemic is in danger of stalling, with lasting consequences, according to a report released at the International AIDS Society conference in Kuala Lumpur this […]

With study of injecting drug users, preventive HIV medicine demonstrates protective value to all at high risk

By on .

CDC releases updated Guidance for Pre-Exposure Prophylaxis for the Prevention of HIV Infection: PrEP for Injecting Drug Users, while questions on real-world impact remain With a five-year study in Bangkok showing that daily doses of antiretroviral medicine reduced risks of HIV infection among people who inject drugs by at least half, and more with the […]

HVTN 505 Investigator: “We’ve got to keep moving the stone up the hill”

By on .

A week to the day after a monitoring board told organizers of the clinical vaccine research trial known as HVTN 505 to stop inoculating participants, only a few certainties have surfaced. One is that the would be vaccine regimen did not prevent HIV infections. The other is that the search for an effective vaccine will […]

Disappointing vaccine trial news, key populations, PEPFAR blueprint all part of Jhpiego’s “The Present and the Future of HIV Prevention”

By on .

A chart of clinical research trials seeking ways to control HIV transmission makes for an impressive display of tenacity, with interrupted trials, ongoing trials, trials that led to other trials, and new trials in their earliest stages. It includes trials of microbicides, vaccines, antiretroviral-drug-based approaches and all of that in different combinations. It includes heartening […]

AVAC talk: As headlines raise hopes, cure researchers manage expectations and challenges

By on .

There was a time, not long ago, that talk of a cure for HIV was so unrealistic that the topic was all but taboo. More recently talk of an HIV cure is the topic of headlines. First came Timothy Brown, “the Berlin Patient,” free of replicable HIV for more than half a dozen years, since […]

Good Participatory Practice TB drug trial guidelines lay groundwork for research, use of new treatments

By on .

If you consider all the years that time stood still in the world of tuberculosis drug research, the most compelling aspect of the Good Participatory Practice Guidelines for TB Drug Trials just released by a Critical Paths to TB Drug Regimens working group is that occasions exist for them to be used. With nearly half […]